Literature DB >> 11596671

Erectile and endothelial dysfunction in Type II diabetes: a possible link.

L De Angelis1, M A Marfella, M Siniscalchi, L Marino, F Nappo, F Giugliano, D De Lucia, D Giugliano.   

Abstract

AIMS/HYPOTHESIS: The aim of this study was to evaluate the relation between erectile dysfunction and endothelial functions, coagulation activation, peripheral and autonomic neuropathy in men with Type II (non-insulin-dependent) diabetes mellitus.
METHODS: We studied 30 Type II diabetic patients with symptomatic erectile dysfunction and 30 potent diabetic patients matched for age and disease. Endothelial functions were assessed with the L-arginine test, plasma thrombomodulin and cell adhesion molecules circulating concentrations. Haemostasis was evaluated with markers of thrombin activation and fibrinolysis. Quantitative sensory testing (vibratory, warming, and heat-pain thresholds), cardiovascular reflex tests and 24-h blood pressure monitoring were used to assess peripheral or autonomic neuropathy.
RESULTS: Mean erectile score and HbA1c were 10.5+/-5.8 and 8.3+/-1.6% in patients with erectile dysfunction, and 24.0+/-0.7 and 6.8+/-1.4% in those without erectile dysfunction, respectively (p < 0.001); there was a significant relation between HbA1c and erectile function score in patients with erectile dysfunction (r = -0.45, p = 0.02). The decrease in blood pressure and platelet aggregation in response to L-arginine was lower (p < 0.05-0.02) in patients with erectile dysfunction, whereas soluble thrombomodulin, P-selectin and intercellular cell ahhesion molecule-1 concentrations were higher (p < 0.05-0.02). Indices of coagulation activation (F1 + 2 and D-dimers) and reduced fibrinolysis (PAI-1) were also found to be higher in erectile dysfunction patients. Heat-pain and warm perception thresholds. as well as cardiovascular reflex tests, were most commonly abnormal in patients with erectile dysfunction (p < 0.05). In multivariate analysis, HbA1c, MBP response to L-arginine, P-selectin, indices of coagulation, and quantitative sensory testing were independent predictors of erectile function score. CONCLUSION/
INTERPRETATION: Erectile dysfunction in diabetic men correlates with endothelial dysfunction. A reduced nitric oxide activity might provide a unifying explanation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11596671     DOI: 10.1007/s001250100616

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  21 in total

1.  Routine cardiac assessment is not necessary for all patients with erectile dysfunction.

Authors:  Naif Alhathal; Serge Carrier
Journal:  Can Urol Assoc J       Date:  2011-10       Impact factor: 1.862

2.  Occurrence of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome in patients with abdominal obesity. Where is a sufficient level of testosterone?

Authors:  Juraj Fillo; Jan Breza; Michaela Levčíkova; Jan Luha; Anna Vachulova; Štefan Durdík; Peter Labaš
Journal:  Int Urol Nephrol       Date:  2012-08       Impact factor: 2.370

3.  Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection.

Authors:  K Joseph Hurt; Biljana Musicki; Michael A Palese; Julie K Crone; Robyn E Becker; John L Moriarity; Solomon H Snyder; Arthur L Burnett
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

Review 4.  Erectile dysfunction: interrelationship with the metabolic syndrome.

Authors:  Glenn Matfin; Ali Jawa; Vivian A Fonseca
Journal:  Curr Diab Rep       Date:  2005-02       Impact factor: 4.810

5.  Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men.

Authors:  F Giugliano; K Esposito; C Di Palo; M Ciotola; G Giugliano; R Marfella; M D'Armiento; D Giugliano
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

Review 6.  Etiology and treatment of erectile failure in diabetes mellitus.

Authors:  Donald Richardson; Aaron Vinik
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

7.  The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus.

Authors:  T Radovits; T Bömicke; G Kökény; R Arif; S Loganathan; K Kécsán; S Korkmaz; E Barnucz; P Sandner; M Karck; G Szabó
Journal:  Br J Pharmacol       Date:  2009-03-04       Impact factor: 8.739

Review 8.  Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.

Authors:  Ajay Nehra
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

Review 9.  Assessment of cardiovascular risk in patients with erectile dysfunction: focus on the diabetic patient.

Authors:  Robert A Kloner
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

10.  Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus.

Authors:  A Schäfer; D Fraccarollo; S Pförtsch; U Flierl; C Vogt; J Pfrang; A Kobsar; T Renné; M Eigenthaler; G Ertl; J Bauersachs
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.